AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01207739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin and hydroxychloroquine
Description: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
Study NCT03825666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ProvideXtra® Fresenius Kabi
Description: Improving wellbeeing
Study NCT03622515 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anesthesia level and cerebral perfusion pressure
Description: Anesthetic dose and blood pressure
Study NCT00413166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA)
Description: Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
Study NCT00413166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide (ATO)
Description: Induction: 0.15 mg/kg daily IV beginning day 1
Study NCT01207739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
Study NCT00985881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom prosthetic socket with mechanical vibrators (stochastic resonance)
Description: Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
Study NCT04223687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverage Warning Label
Description: Labels with a pictorial warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research.
Study NCT04223687 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neutral label
Description: Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
Study NCT02277366 — intervention group
Intervention type: PROCEDURE
Intervention: Fluorescence Bronchoscopy/Narrow Band Bronchoscopy
Description: Fluorescence Bronchoscopy and Narrow Band Bronchoscopy are used in the Fluorescence/Narrow Band Bronchoscopy group to make a diagnosis of lung cancer.
Study NCT00879619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study NCT00879619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00879619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT00985881 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional prosthetic socket (current clinical practice)
Description: No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
Study NCT05474716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% ophthalmic solution
Description: Topical Brimonidine tartrate 0.2% bid ophthalmic solution. A selective alpha 2 adrenergic agonist with ocular hypotensive and neuroprotective properties used in glaucoma and ocular hypertension.
Study NCT03008980 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Test
Study NCT02243527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: 6-weeks of inspiratory muscle training
Study NCT02243527 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Inspiratory Muscle Training
Description: A sham training procedure that is meant to elicit no physiologic changes
Study NCT02389946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orsiro DES
Description: Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
Study NCT02389946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience DES
Study NCT01810146 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Digestive functions investigations
Study NCT03340077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medicines Optimisation Review toolkit
Description: The Review tool consist of two items. 'My Clinic companion' and 'MOR consultation form'. 'My clinic companion' (see appendix 1) is a patient-orientated questionnaire that promotes self-review of medications and adherence and will facilitate the pharmacist consultation. The 'MOR consultation form' (see appendix 2), is designed to aid a structured patient consultation using available information from local databases, GP medication histories as well as that obtained directly from the patient. The form also identifies key care providers involved in the patient case, including prior consent to contact with information if required.
Study NCT03340077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Pharmacist review of ART medications
Study NCT00287833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT04938531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform an entry passive exercise test within 48 hours of onset of severe sepsis. Patients then will perform 30-60 min supine passive cycle ergometry exercise 5 days/week.
Study NCT03814629 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Weifuchun
Description: The treatment group（Weifuchun group）was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(vitamin group) was given vitamin tablets (0.2 g), 4 tablets each time, 3 times a day, and 1 hour after a meal.
Study NCT02573896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: 17.5 mg/m2/day of dinutuximab will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
Study NCT00287833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowman-Birk inhibitor concentrate
Description: Given orally
Study NCT02573896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cells
Description: The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.
Study NCT02573896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
Study NCT03948789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy
Description: Magnetic Resonance Imaging-controlled high-focussed ultrasound
Study NCT03948789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myomectomy (laparoscopic or open surgical)
Description: Myomectomy (laparoscopic or open surgical)
Study NCT00114114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day
Study NCT00114114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 3.6 gms sc every 4 weeks
Study NCT00352781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy
Description: nicotine transdermal patches as per product monograph
Study NCT00352781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioural intervention
Description: Smoking cessation counselling and relapse prevention
Study NCT03564665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400mg Magnesium Glycinate BID
Description: 400mg Magnesium Glycinate BID for 8 weeks.
Study NCT03564665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID for 8 weeks.
Study NCT01264965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long acting oxycodone
Description: 10mg twice daily
Study NCT01264965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: extra strength acetaminophen
Description: 1,000 mg twice daily
Study NCT00413166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 1. 12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~2. If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date.
Study NCT00413166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Induction: 9 mg/m2 on day 1 of induction
Study NCT02701920 — intervention group
Intervention type: DEVICE
Intervention: HeartLight hat
Description: HeartLight hat will be worn for up to 1 hour.
Study NCT02701920 — intervention group
Intervention type: DEVICE
Intervention: The HeartLight hat with in-built sensor
Description: The HeartLight hat with in-built sensor will be worn.
Study NCT02701920 — intervention group
Intervention type: DEVICE
Intervention: HeartLight
Description: Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat
Study NCT02701920 — intervention group
Intervention type: DEVICE
Intervention: HeartLight device
Description: HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope
Study NCT02701920 — intervention group
Intervention type: OTHER
Intervention: parental feedback
Description: Questionnaire
Study NCT02701920 — intervention group
Intervention type: OTHER
Intervention: healthcare provider feedback
Description: Questionnaire
Study NCT02181413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Ixazomib citrate capsules
Study NCT02181413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ixazomib citrate placebo-matching capsules
Study NCT03319654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DNA fragmentation by TUNEL assay
Description: Direct DNA fragmentation testing with terminal deoxyuridine nick end labeling (TUNEL) assay.
Study NCT02861989 — intervention group
Intervention type: OTHER
Intervention: qualitative study
Study NCT03241420 — intervention group
Intervention type: DEVICE
Intervention: lung clearance index (LCI)
Description: Determine the utility and sensitivity of the lung clearance index (LCI) technique as a marker of lung injury/small airways disease in adults with chronic lung conditions compared to health adults, adjusting for age, sex, and smoking status.
Study NCT02899754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lung Cancer Screening Decision Tool
Description: This will be a lung cancer screening decision support tool that is web based and provides patients with information about the potential benefits and harms associated with lung cancer screening and helps them to consider their personal values when making a decision about whether to initiate or continue with lung cancer screening.
Study NCT02899754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: This will be a health message regarding prevention and healthy behavior that is not related to lung cancer screening but delivered in a similar modality and taking approximately the same amount of time as the LCSDecTool.
Study NCT03996018 — intervention group
Intervention type: OTHER
Intervention: T-cell lymphocyte responses
Description: T-cell lymphocyte responses to human immunodeficiency virus (HIV) with and without concomitant herpesvirus infections (specifically, the persistence of HIV-specific human CD8 T-cells in the context of antiretroviral therapy (ART).
Study NCT05359016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV testing of women for cervical cancer screening
Description: Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.
Study NCT04423211 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D CRT
Study NCT04423211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT00269386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00556673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol maleate/mometasone furoate
Description: Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.
Study NCT00556673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol maleate/mometasone furoate
Description: Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
Study NCT04423211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT04423211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT04423211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Given SC
Study NCT04423211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC
Study NCT04423211 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT01874782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial electrical stimulation
Description: TES: medical device TRANSAIR: electrodes placed on the forehead and over the mastoid processes using Velcro straps. Treatment protocol: six 30-minute sessions over a two-week period and stimulation variables (bipolar current; 1.0-3.0 milliamp (mA) amplitude, 3.5 ms duration and 77.5 Hz frequency).
Study NCT02592304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dual energy computed tomography
Description: one extra scanning with a dual energy ct.
Study NCT00722592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide
Description: 2.5 mg IV bolus on Days 1,3,5 and 15,17,19 of a 4-week cycle
Study NCT00722592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin (PLD)
Description: 50 mg/m\^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
Study NCT00722592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)
Description: 50 mg/m\^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
Study NCT00722592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EC20
Description: During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.
Study NCT00722592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EC20
Description: During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.
Study NCT02316093 — intervention group
Intervention type: OTHER
Intervention: Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling
Study NCT04083040 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transcatheter aortic valve implantation
Description: 1. Tilt angle.~2. Depth of implantation of the valve.~3. Type of the valve.(Medtronic core valve self expandable valve ,Edwards sapient balloon expandable valve
Study NCT00556673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone proprionate / salmeterol xinafoate
Description: Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.
Study NCT00860262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
Study NCT00860262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan
Description: telmisartan 80mg for the 8w, no titration required
Study NCT00860262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan and amlodipine
Description: telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
Study NCT04160156 — intervention group
Intervention type: DEVICE
Intervention: Long term sensor
Description: Observational study including subjects using long term sensor according to local guidelines and patients preferences
Study NCT00757172 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: panitumumab
Study NCT00757172 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Study NCT00757172 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Study NCT00757172 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: neoadjuvant therapy
Study NCT00757172 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery
Study NCT00757172 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study NCT02417571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM)
Description: 24-hour ambulatory BP monitoring using TM-2430 device (A\&D Company, Tokyo, Japan)
Study NCT01971554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8666
Description: MK-8666, capsules, oral, QD, Days 1 to 14
Study NCT01971554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, capsules, oral, QD, Days 1 to 14
Study NCT01971554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, capsules, oral, QD, Days 1 to 14
Study NCT01806272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
Study NCT01806272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Vitamin B12
Description: Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
Study NCT01806272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Vitamin B12
Description: Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
Study NCT02005276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Lottery
Description: Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.
Study NCT02005276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Lottery
Description: Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.
Study NCT02005276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jackpot Lottery
Description: Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
Study NCT03595254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive
Description: Computerized Cognitive Behavior Therapy program
Study NCT04423211 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT01790685 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone implant
Study NCT03980522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPL-914
Description: KPL-914 (rilonacept) will be provided in its commercially available formulation as a lyophilized powder to be reconstituted for SC administration.~Adult participants (≥ 18 years of age) KPL-914 will be administered as an initial loading dose of 320 mg SC, delivered as 2 subcutaneous injections of 160 mg SC each on Day 0, then 160 mg SC dosed once weekly for 5 subsequent weeks.~Pediatric participants (6 to \<18 years of age) KPL-914 will be administered with an initial loading dose of 4.4 mg/kg, up to a maximum of 320 mg, delivered as 2 subcutaneous injections of 2.2 mg/kg each with a maximum single-injection volume of 2 mL.~Participants considered to be 'treatment responders' will be offered participation in an optional 18-week extension period (EP) in which KPL-914 can be continued for a total duration of KPL-914 treatment of up to 24 weeks.
Study NCT04423211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluciclovine F18
Description: Given IV
Study NCT04423211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV